US FDA Says Shortage of Novo's Weight-Loss Drug Resolved
(Reuters) - A shortage of Danish drugmaker Novo Nordisk's popular weight-loss and diabetes drugs, Wegovy and Ozempic, has been resolved, the U.S. Food and Drug Administration's website showed on Friday. The resolution comes two months after the health regulator said there was no longer a shortage of Eli Lilly's weight-loss and diabetes drugs.
1hon MSN
Compounding pharmacies producing cheaper semaglutide products have been given notice they will soon have to stop, as the drug ...
The FDA has now resolved the shortages of Novo Nordisk and Eli Lilly’s blockbuster weight-loss drugs, which could spell the ...
We will continue to offer access to personalized treatments as allowed by law to meet patient needs,” Hims & Hers CEO said.
The semaglutide shortage has officially ended in the US—which means the GLP-1 drug industry is about to undergo massive changes.
The FDA has declared an end to the shortage of Novo Nordisk’s blockbuster drug semaglutide, threatening the ability for ...
The resolution could potentially restrict how telehealth programs offer cheaper versions known as compounded drugs ...
The Swiss government wants the power take action in the event of critical medicine shortages in future, rather than cantons ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback